News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tau Therapeutics, LLC to Present Posters at American Association for Cancer Research on T-Type Calcium Channel Inhibitors and Interlaced Therapy


3/29/2012 7:02:06 AM

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Tau Therapeutics LLC announced today that its academic collaborators will present three posters at the American Association of Cancer Research’s 103rd annual meeting in Chicago, Illinois, March 31 – April 4, 2012. The posters will highlight the company’s non-toxic, selective T-type calcium channel inhibitors for the treatment of brain and breast cancers. The company’s approach, called Interlaced Therapy™, capitalizes on the central role of calcium influx through T-type calcium channels during cancer cell growth. In pre-clinical studies, T-type calcium channel blockade with Tau’s drugs arrests tumor cells at their most vulnerable metabolic point in the cell cycle, uniquely amplifying the effects of conventional therapies and overcoming drug resistance.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES